Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double‐blind, placebo‐controlled study

BACKGROUND: Levomilnacipran extended release (ER) is a serotonin and norepinephrine reuptake inhibitor approved for major depressive disorder (MDD) in adults. This study was designed to evaluate relapse prevention with levomilnacipran ER in patients with MDD. METHODS: Patients (≥18 years) with MDD (...

Descripción completa

Detalles Bibliográficos
Autores principales: Durgam, Suresh, Chen, Changzheng, Migliore, Raffaele, Prakash, Chandran, Thase, Michael E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590342/
https://www.ncbi.nlm.nih.gov/pubmed/30675739
http://dx.doi.org/10.1002/da.22872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590342/
https://www.ncbi.nlm.nih.gov/pubmed/30675739
http://dx.doi.org/10.1002/da.22872

Ejemplares similares